{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    5,
    6,
    8,
    9,
    34,
    46,
    53,
    56
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.1 - Synopsis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added language to support flat dosing for Study JVDU based on preliminary interim analysis data"
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.1 - Synopsis (Overall Design); Section 1.2 - Schema; Section 4.1.1 - Cohort A",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added language reflecting PK will also be assessed in all cohorts"
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.1 - Synopsis (Number of Participants); Section 9.2 - Sample Size Determination",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended the range of number of study participants from 15-24 to 18-30"
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.1 - Synopsis (Intervention Groups and Duration); Section 6.1 - Study Intervention(s) Administered",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended the Intervention Groups and Duration table and footnotes to reflect the expansion of Cohort B"
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.2 - Schema",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended Schema and footnotes to reflect the expansion of Cohort B"
      },
      {
        "id": "impact_6",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.3 - Schedule of Activities",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended note above table for clarification"
      },
      {
        "id": "impact_7",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.3 - Schedule of Activities, Continued Access Schedule of Activities",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added reference to Section 10.3 in the AE collection row"
      },
      {
        "id": "impact_8",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.3 - Schedule of Activities",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added language stating an investigator designee may also assess the injection site assessments"
      },
      {
        "id": "impact_9",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.3 - Schedule of Activities",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended instructional language in the Administer ramucirumab row"
      },
      {
        "id": "impact_10",
        "amendmentId": "amend_e",
        "affectedSection": "Section 1.3.1 - Pharmacokinetic Sampling Schedule",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended general instructions for PK sampling"
      },
      {
        "id": "impact_11",
        "amendmentId": "amend_e",
        "affectedSection": "Section 2.1 - Study Rationale",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed language related to prior dosing rationale; Added language referencing clinical outcome and PK parameters of IV and SC dosing; Removed sentence referencing Eli Lilly's SC formulation"
      },
      {
        "id": "impact_12",
        "amendmentId": "amend_e",
        "affectedSection": "Section 2.3.1 - Risk Assessment",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended language to allude to recent clinical data for SC ramucirumab"
      },
      {
        "id": "impact_13",
        "amendmentId": "amend_e",
        "affectedSection": "Section 4.1 - Overall Design; Section 9.2.1 - Cohort A",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Described sub-cohorts and cohorts based on updated study design; Removed language about Study JVDT"
      },
      {
        "id": "impact_14",
        "amendmentId": "amend_e",
        "affectedSection": "Section 4.1.1 - Cohort A",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed sentence referencing participants with disease indications where ramucirumab is approved as a monotherapy"
      },
      {
        "id": "impact_15",
        "amendmentId": "amend_e",
        "affectedSection": "Section 4.1.1 - Cohort A",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended language related to enrolling an additional 3 participants into Cohort A"
      },
      {
        "id": "impact_16",
        "amendmentId": "amend_e",
        "affectedSection": "Section 4.1.2 - Cohort B",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Specified additional design elements in Cohort B, which now comprises B1, B2, and B3"
      },
      {
        "id": "impact_17",
        "amendmentId": "amend_e",
        "affectedSection": "Section 4.3.2 - Rationale for Cohort B (Sub-Cohorts B1, B2, and B3) Dose Selection",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added rationale for dose selection and updated dosing table (based on bioavailability of 40%) for new Sub-Cohorts B1, B2, and B3; Removed rationale for initial Cohort B dose selection"
      },
      {
        "id": "impact_18",
        "amendmentId": "amend_e",
        "affectedSection": "Section 5.1 - Inclusion Criteria",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended Inclusion Criterion 3"
      },
      {
        "id": "impact_19",
        "amendmentId": "amend_e",
        "affectedSection": "Section 6.1 - Study Intervention(s) Administered",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added language specifying dosage in Sub-Cohort B1; Specified when interim analysis will be performed (Sub-Cohort B2); Specified ramucirumab dose may be adjusted in Sub-Cohort B3"
      },
      {
        "id": "impact_20",
        "amendmentId": "amend_e",
        "affectedSection": "Section 6.1 - Study Intervention(s) Administered; Section 6.6 - Dose Modification",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Changed injection site reaction grading threshold and moved to Section 6.1 (from Section 6.6)"
      },
      {
        "id": "impact_21",
        "amendmentId": "amend_e",
        "affectedSection": "Section 6.6 - Dose Modification",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed language related to pausing study on the basis of a new safety signal"
      },
      {
        "id": "impact_22",
        "amendmentId": "amend_e",
        "affectedSection": "Section 6.6 - Dose Modification",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added fever as an example of a non-threatening and reversible Grade 3 clinical AE; Moved language referencing Appendix 3 for AE grading to an earlier paragraph"
      },
      {
        "id": "impact_23",
        "amendmentId": "amend_e",
        "affectedSection": "Section 6.6 - Dose Modification",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added a dose reduction for the MD of the newly described dosage regimen"
      },
      {
        "id": "impact_24",
        "amendmentId": "amend_e",
        "affectedSection": "Section 7.3 - Lost to Follow up",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed language related to collection of survival status"
      },
      {
        "id": "impact_25",
        "amendmentId": "amend_e",
        "affectedSection": "Section 9.1 - Statistical Hypotheses",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Specified Ctrough and the approved dose of IV ramucirumab"
      },
      {
        "id": "impact_26",
        "amendmentId": "amend_e",
        "affectedSection": "Section 9.2.1 - Cohort A",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Amended number of participants/duration of PK and safety assessment required before opening enrollment for Cohort B"
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_e",
        "reasonText": "The overall rationale for the amendment is to enable investigation of additional dosage regimens. Preliminary interim analysis data from Study I4T-MC-JVDT, a single-site study in healthy participants who received a single dose of SC or IV ramucirumab indicated a 40% bioavailability for ramucirumab following SC administration (bioavailability previously predicted: >50%). A Sub-Cohort B1 has been added to provide a second-dose level (in addition to cohort A), with the goal to generate PK data from at least 6 participants to inform dosing strategy for Sub-Cohort B2 (loading dose and maintenance weekly dose).",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_e",
        "reasonText": "Based on preliminary interim analysis data from Study I4T-MC-JVDT",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_e",
        "reasonText": "Clarification",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_e",
        "reasonText": "To account for the expansion of Cohort B, to investigate additional dosing regimens based on preliminary interim analysis data from Study I4T-MC-JVDT",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_5",
        "amendmentId": "amend_e",
        "reasonText": "To provide flexibility for sites",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_6",
        "amendmentId": "amend_e",
        "reasonText": "Correction (missed in previous amendment), based on preliminary interim analysis data from Study I4T-MC-JVDT revealing lower bioavailability than the assumption, previously eligible participants for approved ramucirumab monotherapy (2L Gastric, 2L HCC) would have received sub-optimal exposure on starting Cohort A dose",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_7",
        "amendmentId": "amend_e",
        "reasonText": "Clarification that additional enrollment in Cohort A may occur to numerous reasons",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_8",
        "amendmentId": "amend_e",
        "reasonText": "To account for the expansion of Cohort B, to investigate additional dosing regimens",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_9",
        "amendmentId": "amend_e",
        "reasonText": "Allowing participants with mild-to-moderate local injection site reactions due to ramucirumab SC administration to continue to receive it",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_10",
        "amendmentId": "amend_e",
        "reasonText": "Dose modifications are not relevant for the LD",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_11",
        "amendmentId": "amend_e",
        "reasonText": "To account for a newly added LD of 1750 mg and MD of 875 mg QW based on preliminary interim analysis bioavailability data of 40%",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_12",
        "amendmentId": "amend_e",
        "reasonText": "Correction, as long-term follow-up and survival status is not being collected for this study",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_e",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1",
        "afterText": "Language to support flat dosing for Study JVDU",
        "summary": "Added language to support flat dosing based on preliminary interim analysis data from Study I4T-MC-JVDT"
      },
      {
        "id": "change_2",
        "amendmentId": "amend_e",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1, 1.2, 4.1.1",
        "afterText": "PK will also be assessed in all cohorts",
        "summary": "Added language reflecting PK will also be assessed in all cohorts"
      },
      {
        "id": "change_3",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1, 9.2",
        "beforeText": "15-24 participants",
        "afterText": "18-30 participants",
        "summary": "Amended the range of number of study participants from 15-24 to 18-30"
      },
      {
        "id": "change_4",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1, 6.1",
        "afterText": "Intervention Groups and Duration table and footnotes reflect the expansion of Cohort B",
        "summary": "Amended the Intervention Groups and Duration table and footnotes to reflect the expansion of Cohort B"
      },
      {
        "id": "change_5",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.2",
        "afterText": "Schema and footnotes reflect the expansion of Cohort B",
        "summary": "Amended Schema and footnotes to reflect the expansion of Cohort B"
      },
      {
        "id": "change_6",
        "amendmentId": "amend_e",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "Reference to Section 10.3 in the AE collection row",
        "summary": "Added reference to Section 10.3 in the AE collection row"
      },
      {
        "id": "change_7",
        "amendmentId": "amend_e",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "An investigator designee may also assess the injection site assessments",
        "summary": "Added language stating an investigator designee may also assess the injection site assessments"
      },
      {
        "id": "change_8",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "2.1",
        "beforeText": "Language related to prior dosing rationale; sentence referencing Eli Lilly's SC formulation of ramucirumab",
        "afterText": "Language referencing clinical outcome and PK parameters of IV and SC dosing of ramucirumab in Study I4T-MC-JVDT",
        "summary": "Removed language related to prior dosing rationale; Added language referencing clinical outcome and PK parameters; Removed sentence referencing Eli Lilly's SC formulation"
      },
      {
        "id": "change_9",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "2.3.1",
        "afterText": "Language alluding to recent clinical data for SC ramucirumab",
        "summary": "Amended language to allude to recent clinical data for SC ramucirumab"
      },
      {
        "id": "change_10",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1, 9.2.1",
        "beforeText": "Language about Study JVDT",
        "afterText": "Described sub-cohorts and cohorts based on updated study design",
        "summary": "Described sub-cohorts and cohorts based on updated study design; Removed language about Study JVDT"
      },
      {
        "id": "change_11",
        "amendmentId": "amend_e",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1.1",
        "beforeText": "Sentence referencing participants with disease indications where ramucirumab is approved as a monotherapy",
        "summary": "Removed sentence referencing participants with disease indications where ramucirumab is approved as a monotherapy"
      },
      {
        "id": "change_12",
        "amendmentId": "amend_e",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1.2",
        "afterText": "Cohort B now comprises B1, B2, and B3 with additional design elements",
        "summary": "Specified additional design elements in Cohort B, which now comprises B1, B2, and B3"
      },
      {
        "id": "change_13",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.3.2",
        "beforeText": "Rationale for initial Cohort B dose selection",
        "afterText": "Rationale for dose selection and updated dosing table (based on bioavailability of 40%) for new Sub-Cohorts B1, B2, and B3",
        "summary": "Added rationale for dose selection and updated dosing table for new Sub-Cohorts; Removed rationale for initial Cohort B dose selection"
      },
      {
        "id": "change_14",
        "amendmentId": "amend_e",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1",
        "afterText": "Amended Inclusion Criterion 3",
        "summary": "Amended Inclusion Criterion 3 for clarification"
      },
      {
        "id": "change_15",
        "amendmentId": "amend_e",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1",
        "afterText": "Language specifying dosage in Sub-Cohort B1; when interim analysis will be performed (Sub-Cohort B2); ramucirumab dose may be adjusted in Sub-Cohort B3",
        "summary": "Added language specifying dosage in Sub-Cohort B1, interim analysis timing for Sub-Cohort B2, and dose adjustment for Sub-Cohort B3"
      },
      {
        "id": "change_16",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1, 6.6",
        "beforeText": "Injection site reaction grading threshold in Section 6.6",
        "afterText": "Changed injection site reaction grading threshold and moved to Section 6.1",
        "summary": "Changed injection site reaction grading threshold and moved from Section 6.6 to Section 6.1"
      },
      {
        "id": "change_17",
        "amendmentId": "amend_e",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "6.6",
        "beforeText": "Language related to pausing study on the basis of a new safety signal",
        "summary": "Removed language related to pausing study on the basis of a new safety signal"
      },
      {
        "id": "change_18",
        "amendmentId": "amend_e",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.6",
        "afterText": "Fever as an example of a non-threatening and reversible Grade 3 clinical AE",
        "summary": "Added fever as an example of a non-threatening and reversible Grade 3 clinical AE"
      },
      {
        "id": "change_19",
        "amendmentId": "amend_e",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.6",
        "afterText": "Dose reduction for the MD of the newly described dosage regimen (LD of 1750 mg and MD of 875 mg QW)",
        "summary": "Added a dose reduction for the MD of the newly described dosage regimen based on 40% bioavailability data"
      },
      {
        "id": "change_20",
        "amendmentId": "amend_e",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "7.3",
        "beforeText": "Language related to collection of survival status",
        "summary": "Removed language related to collection of survival status"
      },
      {
        "id": "change_21",
        "amendmentId": "amend_e",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.1",
        "afterText": "Specified Ctrough and the approved dose of IV ramucirumab",
        "summary": "Specified Ctrough and the approved dose of IV ramucirumab for clarification"
      },
      {
        "id": "change_22",
        "amendmentId": "amend_e",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.2.1",
        "afterText": "Amended number of participants/duration of PK and safety assessment required before opening enrollment for Cohort B",
        "summary": "Amended number of participants/duration of PK and safety assessment required before opening enrollment for Cohort B"
      }
    ],
    "summary": {
      "impactCount": 26,
      "reasonCount": 12,
      "changeCount": 22
    }
  }
}